PGN36

PGN36 is a selective cannabinoid CB2 receptor (CB2R) antagonist with Kis of 0.09 µM and >40 µM for CB2R and CB1R, respectively. PGN36 abolishes the increase in collagen type I gene expression by the inducer of bone activity. PGN36 is able to cross the blood-brain barrier. PGN36 can be used for the study of frontotemporal dementia (FTD) [1][2].

Product Specifications

CAS Number

[1564253-75-3]

UNSPSC

12352005

Target

Cannabinoid Receptor

Type

Reference compound

Related Pathways

GPCR/G Protein; Neuronal Signaling

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology; Neurological Disease

Assay Protocol

https://www.medchemexpress.com/pgn36.html

Purity

99.74

Solubility

DMSO : 12.5 mg/mL (ultrasonic; warming; heat to 60°C)

Smiles

O=[N+](C1=CC2=C(N(CC3=CC=CC=C3)N=C2OCC4CCCCC4)C=C1)[O-]

Molecular Formula

C21H23N3O3

Molecular Weight

365.43

References & Citations

[1]González-Naranjo P, et al. New cannabinoid receptor antagonists as pharmacological tool. Bioorg Med Chem. 2020 Oct 1;28 (19) :115672. |[2]Silva-Llanes I, et al. Targeting CB2 receptor with a novel antagonist reverses cognitive decline, neurodegeneration and pyroptosis in a TAU-dependent frontotemporal dementia mouse model. Brain Behav Immun. 2025 Mar 11;127:251-268.